Analysts Set Expectations for KYMR FY2029 Earnings

Kymera Therapeutics, Inc. (NASDAQ:KYMR) – Stock analysts at Brookline Capital Management issued their FY2029 earnings estimates for Kymera Therapeutics in a report released on Monday, January 6th. Brookline Capital Management analyst L. Cann forecasts that the company will earn ($6.44) per share for the year. The consensus estimate for Kymera Therapeutics’ current full-year earnings is ($2.79) per share.

A number of other research analysts have also weighed in on the stock. Morgan Stanley boosted their target price on Kymera Therapeutics from $45.00 to $49.00 and gave the stock an “equal weight” rating in a report on Wednesday, November 6th. Leerink Partners restated an “outperform” rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a report on Friday, December 27th. BTIG Research assumed coverage on shares of Kymera Therapeutics in a report on Tuesday, December 10th. They issued a “buy” rating and a $60.00 target price for the company. Truist Financial restated a “buy” rating and set a $53.00 price target (down from $54.00) on shares of Kymera Therapeutics in a research note on Friday, November 1st. Finally, Oppenheimer raised their price target on Kymera Therapeutics from $52.00 to $56.00 and gave the stock an “outperform” rating in a research report on Friday, September 27th. Three equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Kymera Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $55.38.

Kymera Therapeutics Stock Performance

NASDAQ KYMR opened at $40.52 on Wednesday. Kymera Therapeutics has a one year low of $25.46 and a one year high of $53.27. The business has a fifty day moving average price of $44.20 and a 200 day moving average price of $43.92. The company has a market cap of $2.62 billion, a P/E ratio of -17.32 and a beta of 2.19.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings results on Thursday, October 31st. The company reported ($0.82) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.01. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The firm had revenue of $3.74 million for the quarter, compared to analyst estimates of $10.34 million. During the same period last year, the company posted ($0.90) EPS. Kymera Therapeutics’s quarterly revenue was down 20.9% compared to the same quarter last year.

Insider Activity at Kymera Therapeutics

In other Kymera Therapeutics news, insider Ellen Chiniara sold 3,129 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $41.75, for a total transaction of $130,635.75. Following the transaction, the insider now owns 54,826 shares of the company’s stock, valued at $2,288,985.50. The trade was a 5.40 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 15.82% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Kymera Therapeutics

Hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. boosted its stake in Kymera Therapeutics by 212.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 140,491 shares of the company’s stock worth $6,649,000 after purchasing an additional 95,547 shares during the period. Franklin Resources Inc. boosted its stake in shares of Kymera Therapeutics by 35.1% during the third quarter. Franklin Resources Inc. now owns 29,440 shares of the company’s stock worth $1,356,000 after buying an additional 7,647 shares during the period. Wellington Management Group LLP grew its holdings in shares of Kymera Therapeutics by 7.2% during the third quarter. Wellington Management Group LLP now owns 4,618,359 shares of the company’s stock worth $218,587,000 after buying an additional 308,954 shares during the last quarter. Quarry LP acquired a new position in Kymera Therapeutics in the 3rd quarter valued at about $95,000. Finally, HighTower Advisors LLC purchased a new stake in Kymera Therapeutics during the 3rd quarter valued at approximately $494,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.